Lineage Cell Therapeutics Inc (LCTX)vsEli Lilly and Company (LLY)
LCTX
Lineage Cell Therapeutics Inc
$0.98
-4.55%
HEALTHCARE · Cap: $248.63M
LLY
Eli Lilly and Company
$1,369.93
-3.76%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 660773% more annual revenue ($86.46B vs $13.08M). LLY leads profitability with a 31.9% profit margin vs -246.6%. LLY appears more attractively valued with a PEG of 1.36. LLY earns a higher WallStSmart Score of 74/100 (B).
LCTX
Avoid18
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.0%
Fair Value
$11.28
Current Price
$0.98
$10.30 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : LCTX
The strongest argument for LCTX centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : LCTX
The primary concerns for LCTX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
LCTX profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
LCTX carries more volatility with a beta of 1.69 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 18/100), backed by strong 31.9% margins and 38.6% revenue growth. LCTX offers better value entry with a 84.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage Cell Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?